Rottlerin: Bases for a Possible Usage in Psoriasis

Author(s): Emanuela Maioli, Giuseppe Valacchi

Journal Name: Current Drug Metabolism

Volume 11 , Issue 5 , 2010

Become EABM
Become Reviewer
Call for Editor


Rottlerin is a natural polyphenolic compound, which was initially indicated and marketed as a PKC δ inhibitor and recently proposed and patented as an anti-hypertensive drug. In vitro results from our Laboratory and data from the literature suggest a potential use of Rottlerin in the treatment/control of psoriasis, a skin disease characterized by abnormal cellular proliferation, abnormal angiogenesis and inflammation. Rottlerin, indeed, is an antioxidant and a potent inhibitor of the transcription factor NFκB, a key mediator of immune responses and a crucial regulator of cell cycle and apoptosis in immune cells, endothelial cells and keratinocytes. Herein, we will review the multiple activities of Rottlerin (antioxidant, antiproliferative, antiangiogenic and anti-inflammatory) that give to the drug the potential to be used as a new therapeutic approach against psoriasis.

Keywords: Rottlerin, NFκB, Inflammation, Angiogenesis, Proliferation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [425 - 430]
Pages: 6
DOI: 10.2174/138920010791526097
Price: $65

Article Metrics

PDF: 14